Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
77.78%
-
Total 13F principal
-
$438,570,500
-
Principal change
-
+$2,857,000
-
Total reported market value
-
$343,421,900
-
Number of holders
-
35
-
Value change
-
-$798,028
-
Number of buys
-
14
-
Number of sells
-
23
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q4 2020
As of 31 Dec 2020,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
35 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$438,570,500
in principal (par value) of the bond.
The largest 10 bondholders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Silver Point Capital L.P., DeepCurrents Investment Group LLC, UBS ASSET MANAGEMENT AMERICAS INC, WOLVERINE ASSET MANAGEMENT LLC, ADVENT CAPITAL MANAGEMENT /DE/, Whitebox Advisors LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, OAKTREE CAPITAL MANAGEMENT LP, and Kohlberg Kravis Roberts & Co. L.P..
This page lists
35
institutional bondholders reporting positions
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.